Guided Therapeutics (GTHP) Payables (2010 - 2025)

Guided Therapeutics has disclosed Payables across 16 years of filings, most recently posting $2.5 million for Q4 2025.

• Payables for Q4 2025 came in at $2.5 million, up 12.9% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.5 million (up 12.9% YoY), and the FY2025 annual result was $2.5 million, up 12.9% from the prior year.
• Payables came in at $2.5 million for Q4 2025 at Guided Therapeutics, down from $2.8 million in the prior quarter.
• In the past five years, Payables ranged from a high of $2.8 million in Q3 2025 to a low of $51770.0 in Q1 2023.
• The 5-year median for Payables is $2.2 million (2022), against an average of $2.0 million.
• Across the five-year window, Payables tumbled 97.92% in 2023 and surged 3662.8% in 2024, its largest moves.
• Guided Therapeutics' Payables stood at $135000.0 in 2021, then surged by 1561.16% to $2.2 million in 2022, then decreased by 8.59% to $2.0 million in 2023, then advanced by 8.93% to $2.2 million in 2024, then increased by 12.9% to $2.5 million in 2025.
• The last three Payables figures came in at $2.5 million (Q4 2025), $2.8 million (Q3 2025), and $2.7 million (Q2 2025), per Business Quant data.